[Possibilities of estimation of breast cancer targeted therapy cardiotoxicity in routine clinical practice].
To estimate cardiotoxicity of targeted therapy of breast cancer by the results of methods of investigation, which are used in routine clinical practice. We have made a retrospective analysis of medical documentation of patients with breast cancer, which are given trastuzumab in mono regimen and as a part of antitumor chemotherapy. An average number of chemotherapy's courses is 10,3±1,9. Such methods as echocardiography and electrocardiography, physical examination are ordinary used to estimate the cardiotoxicity in routine clinical practice. Revealed dynamic of indices shows that pathological changes of cardiovascular system developed during using trastuzumab do not reach the level of generally accepted sings of cardiotoxicity. Methods of diagnostics, which are used in routine clinical practice nowadays do not allow to reveal the early sings of myocardial damage. The question about commissioning of modern technologies in aim of early examination of myocardial dysfunction is still relevant.